Abstract: The present invention relates to novel, selective, radiolabelled compound having monoacylglycerol lipase (MGL) affinity which are useful for imaging and quantifying MGL receptor expression, distribution and enzyme occupancy in tissues, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, the use of such compounds and compositions for imaging a tissue, cells or a host, in vitro or in vivo and to precursors of said compounds.

Abstract: The present invention provides peptide hydrogelators capable of forming hydrogels as carriers of active ingredients and acting as sustained or controlled release drug delivery systems.

Abstract: Rigidified pentadentate chelating agents of Formulae (I) and (II), which are useful for the [Al18F]2+ labelling of biomolecules are provided. The rigidified pentadentate chelating agents are used to form coordination complexes with [Al18F]2+, which are particularly advantageous for use as tracers in molecular imaging techniques.

Abstract: A compound according to Formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, wherein X1 and X2 are each independently 18F or 19F; R1 and R2 are each independently alkyl, amine, perfluoroalkyl, alkenyl, alkynyl, aryl, or aralkenyl; and R3 is H, halo, alkyl, alkyl ester, alkenyl, alkynyl, aryl, or aralkenyl; or wherein: R1 and R3 or R2 and R3 join to form a 6-membered cycloalkyl or heterocyclyl; or R1 and R3, R2 and R3, or R1, R2, and R3 join to form a substituted or unsubstituted polycyclic ring, wherein the polycyclic ring comprises fused cycloalkyl, heterocycloalkyl, aryl, or heteroaryl rings.

Abstract: Provided is a bio-based material having an antibacterial effect, comprising a polymer represented by a formula (1) or a mixture of the polymer represented by the formula (1) and polyethylene glycol as an antibacterial active ingredient. The use of the bio-based material is also mentioned. The antibacterial bio-based material has excellent, stable and long-lasting antibacterial activity, and has remarkable antibacterial effects against various bacteria and fungi. The antibacterial bio-based material also has excellent biodegradability and biocompatibility, is derived from bio-based products produced by microbial fermentation, has high safety and is suitable for industrial production and large-scale use.

Abstract: A method of inhibiting cancer cell viability may include contacting cancer cells and a nanocomposite including graphitic C3N4, V2O5, and MgAl2O4 in a mass relationship to each other in a range of 5 to 15:2 to 7:75 to 95. The concentration range of the nanocomposite at the time of contacting the nanocomposite is in the range of 10.0 micrograms per milliliters (g/mL) to 500 ?g/mL, thereby inhibiting the growth of the cancer cells by at least 85%.

Abstract: The present disclosure sets forth novel compounds and compositions including heteroaromatic silicon-fluoride-acceptors, which are useful for PET scanning. The present disclosure further includes novel methods of 18F imaging for PET scanning, the methods comprising the preparation of conjugates and bioconjugates of biological ligands of interest with heteroaromatic silicon-fluoride-acceptors. In certain embodiments the invention is practiced in the form of a kit.

Abstract: A pharmacological composition contains a complex having a structurally modified RGD polypeptide a radionuclide. This pharmacological composition is useful for diagnosis or treatment of the integrin ?v?3-positive tumors. The pharmacological composition may further contain an immunotherapeutic medicament and an optional nanoantibody molecular imaging probe. Treatment with a PD-L1 blockade after the targeted radioactive therapy can archive the optimal synergic efficacy. Moreover, with administration of PD-1 or PD-L1 nanoantibody molecular imaging probe, expression of PD-1 or PD-L1 in the tumor after targeted radiotherapy can be observed.

Abstract: The present invention relates to a compound according to formula (V): or a pharmaceutically acceptable salt thereof, optionally containing a chelated radioactive cation and wherein F is optionally 18F.

Abstract: A radiopaque composition is provided that includes an inorganic opacifying agent distributed through an aqueous gelatinous substance in an aqueous solvent. A process for making a radiodense vascular fill composition includes adding a gelatinous substance to an aqueous solution. An inorganic opacifying agent suspension is formed in a saline solution or water. The inorganic opacifying agent and gelatin are mixed with water or saline. A process of imaging a vascular system of a subject includes placing a subject under anesthesia or sedation and exsanguinating the subject. An isotonic fluid is then flushed through the vascular system and the radiopaque composition is infused into the subject circulatory system at a temperature of 40 degrees Celsius or greater. After waiting a given time interval for the radiopaque composition to cool and form a solid gel, an imaging scan is performed on the subject.

Abstract: The present invention provides dioxetane-based chemiluminescence probes, more specifically fluorophore-tethered dioxetane-based chemiluminescence probes and compositions thereof. The chemiluminescence probes disclosed are useful for both diagnostics and in vivo imaging.

Abstract: There is described a method for the preparation of an aqueous magnetic resonance imaging medium, said method comprising the steps of: •(i) preparing a multiphasic solvent system comprising an aqueous component and a non-aqueous component, said solvent comprising a target substrate and a SABRE hyperpolarisation transfer catalyst; •(ii) adding H2 or parahydrogen gas; •(iii) agitating the solvent system to form an emulsion thereby transferring the spin order from the hyperpolarisation transfer catalyst to the target substrate; •(v) adding a solvent phase-separation promoter; and •(vi) separating the non-aqueous component and the aqueous component wherein the aqueous component contains the hyperpolarised target substrate and provides the aqueous magnetic resonance imaging medium.

Abstract: The present invention relates to a liquid radiopharmaceutical composition comprising a radiopharmaceutical compound according to Formula I or a pharmaceutically acceptable salt thereof; and a buffer, wherein the buffer provides the radiopharmaceutical composition with a pH of about 7.0 to about 8.9. The present invention also relates to a pre-composition, starter composition, and kit, which can find use in preparing the liquid radiopharmaceutical composition, as well as to methods of preparing the liquid radiopharmaceutical composition, and medical uses of the liquid radiopharmaceutical composition.

Abstract: The present invention provides in certain embodiments a carcinoma-targeting conjugate comprising Formula I: T-L-X wherein T is a SSTR2 targeting ligand, L is a linker, and X is a chelator, for the therapeutic treatment of cancer, and methods of use thereof.

Abstract: Theranostic agents incorporating a chelating moiety that can chelate a radioactive metal isotope and a PSMA-targeting moiety are disclosed herein. The theranostic agents, which can be used to treat and/or detect cancers associated with increased PSMA expression, have the formula: and include complexes, anions or salts thereof. R1 includes a chelating moiety; a is 0 or 1; n is an integer from 12 to 21; and R2 includes a prostate specific membrane antigen (PSMA)-targeting moiety. Optionally, the chelating moiety is chelated to a metal atom, where the metal atom is a positron or single photon emitting metal isotope, or an alpha, beta, or Auger emitting metal isotope.

Abstract: A chemical compound that binds to nerves and provides for visualization of the nerves using computed tomography or x-ray may include at least two iodo groups bonded to a local anesthetic with an aromatic functional group/benzene ring, wherein the local anesthetic is capable of binding to a nerve. The chemical compound may have the chemical structure C6H2IxR, wherein x is 2 or 3; R is an amino group or NHR1; and R1 is an amide group, such as —CON(CH2CH3)2.

Abstract: An otic application for treatment of an upper respiratory infection of an upper respiratory system of a human or animal subject, the otic application including an antiviral agent to inhibit viral replication or infection, and at least one oil to facilitate transport of the antiviral agent to the upper respiratory system of the subject, such that the otic application is configured for use within an ear of the subject for treating the upper respiratory infection within the subject, and such that the otic application is configured to diffuse through an intact tympanic membrane of the subject from the ear and deliver the antiviral agent to the upper respiratory system of the subject, thereby treating the upper respiratory infection.

Abstract: Compositions comprising high levels of high specific activity copper-64, and process for preparing said compositions. The compositions comprise from about 2 Ci to about 15 Ci of copper-64 and have specific activities up to about 3800 mCi copper-64 per microgram of copper. The processes for preparing said compositions comprise bombarding a nickel-64 target with a low energy, high current proton beam, and purifying the copper-64 from other metals by a process comprising ion exchange chromatography or a process comprising a combination of extraction chromatography and ion exchange chromatography.

Abstract: Aspects of the disclosure provide biconjugatable labels, labeled biomolecules, and methods of using and making the same.

Abstract: Cyclooctene conjugates of therapeutic or diagnostic agents have improved aqueous solubility and can release the agents upon contact with a tetrazine-containing biomaterial. The cyclooctene conjugates provide site-selective delivery of agents at the location of the tetrazine-containing biomaterial in a subject. The compositions and methods have applications in the treatment of various diseases or conditions including cancer, tumor growths, and bacterial infections.